Exact Sciences Corporation (NASDAQ:EXAS) insider Kevin T. Conroy sold 134,057 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) opened at $59.27 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. Exact Sciences Corporation has a fifty-two week low of $13.05 and a fifty-two week high of $63.60.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm had revenue of $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. During the same period last year, the company earned ($0.36) earnings per share. The company’s revenue for the quarter was up 158.4% on a year-over-year basis. analysts anticipate that Exact Sciences Corporation will post -1.12 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of EXAS. Fortaleza Asset Management Inc. acquired a new stake in shares of Exact Sciences Corporation during the second quarter worth $106,000. Krilogy Financial LLC lifted its holdings in shares of Exact Sciences Corporation by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in shares of Exact Sciences Corporation by 2,925.7% during the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares during the period. Finally, Financial Architects Inc lifted its holdings in shares of Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after purchasing an additional 2,035 shares during the period. 86.04% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on the company. Jefferies Group LLC increased their price objective on Exact Sciences Corporation to $60.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. Robert W. Baird increased their price objective on Exact Sciences Corporation from $49.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 31st. Vetr downgraded Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $38.66 price objective for the company. in a report on Thursday, August 3rd. Canaccord Genuity reissued a “buy” rating and issued a $45.00 price objective on shares of Exact Sciences Corporation in a report on Thursday, September 7th. Finally, Benchmark Co. reissued a “buy” rating and issued a $60.00 price objective (up from $50.00) on shares of Exact Sciences Corporation in a report on Tuesday, October 31st. Eight equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $49.98.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Exact Sciences Corporation (EXAS) Insider Sells $7,976,391.50 in Stock” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/insider-selling-exact-sciences-corporation-exas-insider-sells-7976391-50-in-stock/1725072.html.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.